iBio, Inc.  announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. for the joint development of products and manufacturing facilities for the Chinese biopharmaceutical market, utilizing iBio’s technology.  The first product focus selected pursuant to the agreement executed between iBio and CC-Pharming will be a therapeutic antibody, with additional, mutually selected products to be added to the venture as it proceeds. Service fees payable to iBio for this firs...